Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 94 P265 | DOI: 10.1530/endoabs.94.P265

SFEBES2023 Poster Presentations Reproductive Endocrinology (42 abstracts)

Non-invasive assessment of liver abnormalities in turner syndrome: A Follow-up Study

Matilde Calanchini 1 , Alexandra Shipley 1 , Jeremy Cobbold 2,3 , Jeremy Tomlinson 4,3 & Helen Turner 1

1Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, University of Oxford, Oxford, United Kingdom. 2Department of Gastroenterology and Hepatology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom. 3National Institute for Health Research, Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom. 4Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital, Oxford, United Kingdom

Background: We have previously reported abnormal liver function tests (LFTs), FIB-4 scores and liver stiffness measurements (LSM, Fibroscan) in patients with Turner syndrome (TS), but longitudinal data defining the impact of TS on liver phenotype are limited.

Methods: We undertook a retrospective longitudinal follow-up audit (OUH; 8348) of 24 women with TS who had abnormal LFTs and underwent at least 2 assessments (median age at baseline 43 years, range 20+/-64). Biochemical measurements (ALT/AST/GGT) and LSM were collected. FIB-4 scores <1.3 were indicative of a low risk of advanced fibrosis; scores >2.67 indicated a high risk of advanced fibrosis. LSM >8kPa indicated significant fibrosis, and >13kPa was suggestive of cirrhosis.

Results: After 4.5+/-1.4 years observation period, in those women with normal AST and ALT at baseline, 53% (8/15) and 50% (5/10) respectively became abnormal, subsequently re-normalising in 3 and 2. In those with baseline abnormal transaminases, 2/7 and 4/12 were normal at follow-up. GGT measurements showed less fluctuation; one patient normalising. Considering FIB-4 scores, 11/20 women remained in the low-risk category, while 3 became indeterminate (comorbidity/drug related), and 3 initially considered indeterminate normalised. Fifteen women had a new Fibroscan after a period of 4.6+/-1.8 years. 13% (2/15) showed LSM suggesting significant fibrosis, including one with LSM >13kPa. Among 14 women who had available LSM measurements at baseline and follow-up, most improved (71%, 10/14): 79% (11) remained below the LSM cut-off of 8kPa, two entered the low-risk and the one with the high LSM measurement improved from 13.9 to 9.4kPa.

Conclusion: Fluctuations in aminotransferases and non-invasive scores (FIB-4) are common in patients with TS. Reassuringly, LSM showed no significant fibrosis in the majority (87%) of patients and no progression to high risk categories. Further longitudinal analysis of liver phenotype in patients with TS in larger cohorts is now warranted.

Volume 94

Society for Endocrinology BES 2023

Glasgow, UK
13 Nov 2023 - 15 Nov 2023

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.